AN INSTANCE GROWING OF BLOOD-PLASMA PROTEIN AND LIVER FUNCTION, BY CHEMOTHERAPEUTIC DOSE OF ANTICANCER DRUG ABRAXANE AND FAMARA IN BREAST CANCER PATIENTS OF HUMAN FEMALE.
Main Article Content
Keywords
.
Abstract
In all over the world, the present harmful life threatening situation to face women despite using several effective drugs to reduced the possibility of spreading breast cancer become dominant. The chemotherapeutic chemicals are limited to human (HER2) epidermal growth factor receptor-2. For the purpose of different drugs used against the breast cancer treatment, to evaluate their effects to collect the data of 200 breast cancer women from DHQ Hospital DERA GHAZI KHAN. Our current aims to analysis the blood chemistry of the breast cancer patients and liver functioning test first 5 days and 45 days of the drug use. All the 200 patients are used two different anti-cancer drugs Famara® and Abraxane®. Famara® (Letrozole) is a type of hormone therapy drug and dose of letrozole is one 2.5mg tablet administered once a day without being regards the meals. Abraxane®, the current gold standard for paclitaxel (PTX) delivery, has superiority based effects on breast cancer in nanoparticle albumin-bound technology and their dose 260 mg/m2 IV over 30 minutes every 3 weeks. Despite like these advances, further more novel therapy is urgently needed for the improvement of anti-tumor efficacy for breast cancer. In our study, to analyze that the recombinant of two above clinical drugs of Famara® and Abraxane®. Letrozole acts as inhibitor in the female to suppressing the secretion female secondary hormone like estrogen, estrogen hormone involve in the proliferation of breast cancer cells, letrozole reduce the estrogen hormone secretion in female body during the puberty and the possibility of breast cancer is also reduced. Abraxane® migrates to the tumor region by the mechanism of human serum albumin(HSA) and recognize the HE2(+) breast cancer cells to synthesis of EDC/NHS which promote the tubulin dimers assemble to microtubule and tubulin dimers stabilizes microtubules by preventing depolymerization. This study revealed that the Abraxane® are better functionality than Famara® because breast cancer cure rate are higher than Famara® and have less side effects.
References
1- Olayioye, M. A., Neve, R. M., Lane, H. A., & Hynes, N. E. (2000). The ErbB signaling network: receptor heterodimerization in development and cancer. The EMBO journal, 19(13), 3159-3167.
2- Yarden, Y., & Sliwkowski, M. X. (2001). Untangling the ErbB signalling network. Nature reviews Molecular cell biology, 2(2), 127-137.
3- Garrett, T. P., McKern, N. M., Lou, M., Elleman, T. C., Adams, T. E., Lovrecz, G. O., ... & Ward, C. W. (2003). The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Molecular cell, 11(2), 495-505.
4- Jorissen, R. N., Walker, F., Pouliot, N., Garrett, T. P., Ward, C. W., & Burgess, A. W. (2003). Epidermal growth factor receptor: mechanisms of activation and signalling. The EGF receptor family, 33-55.
5- Vincenzi, B., Armento, G., Spalato Ceruso, M., Catania, G., Leakos, M., Santini, D., ... & Tonini, G. (2016). Drug-induced hepatotoxicity in cancer patients-implication for treatment. Expert opinion on drug safety, 15(9), 1219-1238.
6- Hanks, S. K., & Hunter, T. (1995). The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification 1. The FASEB journal, 9(8), 576-596.
7- Olayioye, M. A., Neve, R. M., Lane, H. A., & Hynes, N. E. (2000). The ErbB signaling network: receptor heterodimerization in development and cancer. The EMBO journal, 19(13), 3159-3167.
8- Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. science, 235(4785), 177-182.
9- John, T. A., Vogel, S. M., Tiruppathi, C., Malik, A. B., & Minshall, R. D. (2003). Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. American Journal of Physiology-Lung Cellular and Molecular Physiology, 284(1), L187-L196.
10- Maosa, S., Frerichs, L., Schug, Z., Siegel, S., & Mourtada, J. S. (2019). Strong tumor expression of ALDH1A1 is associated with Black race, metabolic disorders, and poor breast cancer outcomes: ALDH1A1 Race and outcomes. Cancer Health Disparities.
11- Sebastian, J., Richards, R. G., Walker, M. P., Wiesen, J. F., Werb, Z., Derynck, R., ... & DiAugustine, R. P. (1998). Activation and function of the epidermal growth factor receptor and erbB-2 during mammary gland morphogenesis. Cell growth & differentiation: the molecular biology journal of the American Association for Cancer Research, 9(9), 777-785.
12- Yarden, Y. (2001). The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. European journal of cancer, 37, 3-8.
13- Tzahar, E., Waterman, H., Chen, X., Levkowitz, G. I. L., Karunagaran, D., Lavi, S., ... & Yarden, Y. (1996). A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Molecular and cellular biology, 16(10), 5276-5287.
14- Gassmann, M., Casagranda, F., Orioli, D., Simon, H., Lai, C., Klein, R., & Lemke, G. (1995). Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature, 378(6555), 390-394.
15- Garrett, T. P., McKern, N. M., Lou, M., Elleman, T. C., Adams, T. E., Lovrecz, G. O., ... & Ward, C. W. (2003). The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Molecular cell, 11(2), 495-505.
16- Benstead, T. J., & Grant, I. A. (2001). Progress in clinical neurosciences: Charcot-Marie-Tooth disease and related inherited peripheral neuropathies. Canadian journal of neurological sciences, 28(3), 199-214.
17- Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. science, 235(4785), 177-182.
18- Sepp-Lorenzino, L., Eberhard, I., Ma, Z., Cho, C., Serve, H., Liu, F., ... & Lupu, R. (1996). Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells. Oncogene, 12(8), 1679-1687.
19- Ullrich, A., & Schlessinger, J. (1990). Signal transduction by receptors with tyrosine kinase activity. Cell, 61(2), 203-212.
20- Taga, T., & Kishimoto, T. (1992). Cytokine receptors and signal transduction. The FASEB journal, 6(15), 3387-3396.
21- Schulze, W. X., Deng, L., & Mann, M. (2005). Phosphotyrosine interactome of the ErbB‐receptor kinase family. Molecular systems biology, 1(1), 2005-0008.
22- Xia, L., Wang, L., Chung, A. S., Ivanov, S. S., Ling, M. Y., Dragoi, A. M., ... & Chin, Y. E. (2002). Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation. Journal of Biological Chemistry, 277(34), 30716-30723.
23- Yarden, Y., & Sliwkowski, M. X. (2001). Untangling the ErbB signalling network. Nature reviews Molecular cell biology, 2(2), 127-137.
24- Hynes, N. E., & Lane, H. A. (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews Cancer, 5(5), 341-354.
25- Sorkin, A., Mazzotti, M., Sorkina, T., Scotto, L., & Beguinot, L. (1996). Epidermal growth factor receptor interaction with clathrin adaptors is mediated by the Tyr974-containing internalization motif. Journal of Biological Chemistry, 271(23), 13377-13384.
26- Hauge-Evans, A. C., Evans, D. B., Dowsett, M., & Martin, L. A. (2004, January). Combining the RTK inhibitor AEE788 with tamoxifen or letrozole results in enhanced growth inhibition of hormone-dependent human breast cancer cells. In BREAST CANCER RESEARCH AND TREATMENT (Vol. 88, pp. S32-S33). 233 SPRING STREET, NEW YORK, NY 10013 USA: SPRINGER.
27- Hendriks, B. S., Opresko, L. K., Wiley, H. S., & Lauffenburger, D. (2003). Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo-and heterodimers depends on relative HER2 levels. Journal of Biological Chemistry, 278(26), 23343-23351.
28- Beerli, R. R., Graus-Porta, D., Woods-Cook, K., Chen, X., Yarden, Y., & Hynes, N. E. (1995). Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Molecular and cellular biology, 15(12), 6496-6505.
29- Xia, L., Wang, L., Chung, A. S., Ivanov, S. S., Ling, M. Y., Dragoi, A. M., ... & Chin, Y. E. (2002). Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation. Journal of Biological Chemistry, 277(34), 30716-30723.
30- Yarden, Y., & Sliwkowski, M. X. (2001). Untangling the ErbB signalling network. Nature reviews Molecular cell biology, 2(2), 127-137.
31- Grøvdal, L. M., Stang, E., Sorkin, A., & Madshus, I. H. (2004). Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. Experimental cell research, 300(2), 388-395
32- Sabnis, G. J., Jelovac, D., Long, B. J., Schayowitz, A., Belosay, A., & Brodie, A. M. (2006). Mammalian target of rapamycin (mTOR) as a target in human breast cancer cells that have acquired resistance to aromatase inhibitor letrozole. Cancer Research, 66(8_Supplement), 547-547.
33- Schwartzberg, L. S., Franco, S. X., Florance, A., O'Rourke, L., Maltzman, J., & Johnston, S. (2010). Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor–positive metastatic breast cancer. The oncologist, 15(2), 122-129.
34- Traina, T. A., Rugo, H., Caravelli, J., Yeh, B., Panageas, K., Bruckner, J., ... & Dickler, M. (2006). Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC). Journal of Clinical Oncology, 24(18_suppl), 3050-3050.
35- Wei, X., Juan, Z. X., Min, F. X., Nan, C., Hua, Z. X., Qing, F. Z., & Zheng, L. (2011). Recombinant immunotoxin anti-c-Met/PE38KDEL inhibits proliferation and promotes apoptosis of gastric cancer cells. Journal of Experimental & Clinical Cancer Research, 30, 1-7.
36- Van Tellingen, O., Huizing, M. T., Panday, V. R., Schellens, J. H. M., Nooijen, W. J., & Beijnen, J. H. (1999). Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. British journal of cancer, 81(2), 330-335.
37- Sparreboom, A., Van Zuylen, L., Brouwer, E., Loos, W. J., De Bruijn, P., Gelderblom, H., ... & Verweij, J. (1999). Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer research, 59(7), 1454-1457.
38- Biakhov, M. Y., Kononova, G. V., Iglesias, J., Desai, N., Bhar, P., Schmid, A. N., & Loibl, S. (2010). nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study. Expert opinion on drug safety, 9(4), 515-523.
39- Crosasso, P., Ceruti, M., Brusa, P., Arpicco, S., Dosio, F., & Cattel, L. (2000). Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. Journal of Controlled Release, 63(1-2), 19-30.
40- Pfister, C. U., Martoni, A., Zamagni, C., Lelli, G., De Braud, F., Souppart, C., ... & Hornberger, U. (2001). Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara®) in breast cancer patients. Biopharmaceutics & drug disposition, 22(5), 191-197.
41- Vincenzi, B., Armento, G., Spalato Ceruso, M., Catania, G., Leakos, M., Santini, D., ... & Tonini, G. (2016). Drug-induced hepatotoxicity in cancer patients-implication for treatment. Expert opinion on drug safety, 15(9), 1219-1238.
42- Mast, N., Lin, J. B., & Pikuleva, I. A. (2015). Marketed drugs can inhibit cytochrome P450 27A1, a potential new target for breast cancer adjuvant therapy. Molecular pharmacology, 88(3), 428-436.
43- Li, Y. F., Fu, S., Hu, W., Liu, J. H., Finkel, K. W., Gershenson, D. M., & Kavanagh, J. J. (2007). Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. International Journal of Gynecological Cancer, 17(4), 739-763.
2- Yarden, Y., & Sliwkowski, M. X. (2001). Untangling the ErbB signalling network. Nature reviews Molecular cell biology, 2(2), 127-137.
3- Garrett, T. P., McKern, N. M., Lou, M., Elleman, T. C., Adams, T. E., Lovrecz, G. O., ... & Ward, C. W. (2003). The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Molecular cell, 11(2), 495-505.
4- Jorissen, R. N., Walker, F., Pouliot, N., Garrett, T. P., Ward, C. W., & Burgess, A. W. (2003). Epidermal growth factor receptor: mechanisms of activation and signalling. The EGF receptor family, 33-55.
5- Vincenzi, B., Armento, G., Spalato Ceruso, M., Catania, G., Leakos, M., Santini, D., ... & Tonini, G. (2016). Drug-induced hepatotoxicity in cancer patients-implication for treatment. Expert opinion on drug safety, 15(9), 1219-1238.
6- Hanks, S. K., & Hunter, T. (1995). The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification 1. The FASEB journal, 9(8), 576-596.
7- Olayioye, M. A., Neve, R. M., Lane, H. A., & Hynes, N. E. (2000). The ErbB signaling network: receptor heterodimerization in development and cancer. The EMBO journal, 19(13), 3159-3167.
8- Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. science, 235(4785), 177-182.
9- John, T. A., Vogel, S. M., Tiruppathi, C., Malik, A. B., & Minshall, R. D. (2003). Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. American Journal of Physiology-Lung Cellular and Molecular Physiology, 284(1), L187-L196.
10- Maosa, S., Frerichs, L., Schug, Z., Siegel, S., & Mourtada, J. S. (2019). Strong tumor expression of ALDH1A1 is associated with Black race, metabolic disorders, and poor breast cancer outcomes: ALDH1A1 Race and outcomes. Cancer Health Disparities.
11- Sebastian, J., Richards, R. G., Walker, M. P., Wiesen, J. F., Werb, Z., Derynck, R., ... & DiAugustine, R. P. (1998). Activation and function of the epidermal growth factor receptor and erbB-2 during mammary gland morphogenesis. Cell growth & differentiation: the molecular biology journal of the American Association for Cancer Research, 9(9), 777-785.
12- Yarden, Y. (2001). The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. European journal of cancer, 37, 3-8.
13- Tzahar, E., Waterman, H., Chen, X., Levkowitz, G. I. L., Karunagaran, D., Lavi, S., ... & Yarden, Y. (1996). A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Molecular and cellular biology, 16(10), 5276-5287.
14- Gassmann, M., Casagranda, F., Orioli, D., Simon, H., Lai, C., Klein, R., & Lemke, G. (1995). Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature, 378(6555), 390-394.
15- Garrett, T. P., McKern, N. M., Lou, M., Elleman, T. C., Adams, T. E., Lovrecz, G. O., ... & Ward, C. W. (2003). The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Molecular cell, 11(2), 495-505.
16- Benstead, T. J., & Grant, I. A. (2001). Progress in clinical neurosciences: Charcot-Marie-Tooth disease and related inherited peripheral neuropathies. Canadian journal of neurological sciences, 28(3), 199-214.
17- Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. science, 235(4785), 177-182.
18- Sepp-Lorenzino, L., Eberhard, I., Ma, Z., Cho, C., Serve, H., Liu, F., ... & Lupu, R. (1996). Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells. Oncogene, 12(8), 1679-1687.
19- Ullrich, A., & Schlessinger, J. (1990). Signal transduction by receptors with tyrosine kinase activity. Cell, 61(2), 203-212.
20- Taga, T., & Kishimoto, T. (1992). Cytokine receptors and signal transduction. The FASEB journal, 6(15), 3387-3396.
21- Schulze, W. X., Deng, L., & Mann, M. (2005). Phosphotyrosine interactome of the ErbB‐receptor kinase family. Molecular systems biology, 1(1), 2005-0008.
22- Xia, L., Wang, L., Chung, A. S., Ivanov, S. S., Ling, M. Y., Dragoi, A. M., ... & Chin, Y. E. (2002). Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation. Journal of Biological Chemistry, 277(34), 30716-30723.
23- Yarden, Y., & Sliwkowski, M. X. (2001). Untangling the ErbB signalling network. Nature reviews Molecular cell biology, 2(2), 127-137.
24- Hynes, N. E., & Lane, H. A. (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews Cancer, 5(5), 341-354.
25- Sorkin, A., Mazzotti, M., Sorkina, T., Scotto, L., & Beguinot, L. (1996). Epidermal growth factor receptor interaction with clathrin adaptors is mediated by the Tyr974-containing internalization motif. Journal of Biological Chemistry, 271(23), 13377-13384.
26- Hauge-Evans, A. C., Evans, D. B., Dowsett, M., & Martin, L. A. (2004, January). Combining the RTK inhibitor AEE788 with tamoxifen or letrozole results in enhanced growth inhibition of hormone-dependent human breast cancer cells. In BREAST CANCER RESEARCH AND TREATMENT (Vol. 88, pp. S32-S33). 233 SPRING STREET, NEW YORK, NY 10013 USA: SPRINGER.
27- Hendriks, B. S., Opresko, L. K., Wiley, H. S., & Lauffenburger, D. (2003). Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo-and heterodimers depends on relative HER2 levels. Journal of Biological Chemistry, 278(26), 23343-23351.
28- Beerli, R. R., Graus-Porta, D., Woods-Cook, K., Chen, X., Yarden, Y., & Hynes, N. E. (1995). Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Molecular and cellular biology, 15(12), 6496-6505.
29- Xia, L., Wang, L., Chung, A. S., Ivanov, S. S., Ling, M. Y., Dragoi, A. M., ... & Chin, Y. E. (2002). Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation. Journal of Biological Chemistry, 277(34), 30716-30723.
30- Yarden, Y., & Sliwkowski, M. X. (2001). Untangling the ErbB signalling network. Nature reviews Molecular cell biology, 2(2), 127-137.
31- Grøvdal, L. M., Stang, E., Sorkin, A., & Madshus, I. H. (2004). Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. Experimental cell research, 300(2), 388-395
32- Sabnis, G. J., Jelovac, D., Long, B. J., Schayowitz, A., Belosay, A., & Brodie, A. M. (2006). Mammalian target of rapamycin (mTOR) as a target in human breast cancer cells that have acquired resistance to aromatase inhibitor letrozole. Cancer Research, 66(8_Supplement), 547-547.
33- Schwartzberg, L. S., Franco, S. X., Florance, A., O'Rourke, L., Maltzman, J., & Johnston, S. (2010). Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor–positive metastatic breast cancer. The oncologist, 15(2), 122-129.
34- Traina, T. A., Rugo, H., Caravelli, J., Yeh, B., Panageas, K., Bruckner, J., ... & Dickler, M. (2006). Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC). Journal of Clinical Oncology, 24(18_suppl), 3050-3050.
35- Wei, X., Juan, Z. X., Min, F. X., Nan, C., Hua, Z. X., Qing, F. Z., & Zheng, L. (2011). Recombinant immunotoxin anti-c-Met/PE38KDEL inhibits proliferation and promotes apoptosis of gastric cancer cells. Journal of Experimental & Clinical Cancer Research, 30, 1-7.
36- Van Tellingen, O., Huizing, M. T., Panday, V. R., Schellens, J. H. M., Nooijen, W. J., & Beijnen, J. H. (1999). Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. British journal of cancer, 81(2), 330-335.
37- Sparreboom, A., Van Zuylen, L., Brouwer, E., Loos, W. J., De Bruijn, P., Gelderblom, H., ... & Verweij, J. (1999). Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer research, 59(7), 1454-1457.
38- Biakhov, M. Y., Kononova, G. V., Iglesias, J., Desai, N., Bhar, P., Schmid, A. N., & Loibl, S. (2010). nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study. Expert opinion on drug safety, 9(4), 515-523.
39- Crosasso, P., Ceruti, M., Brusa, P., Arpicco, S., Dosio, F., & Cattel, L. (2000). Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. Journal of Controlled Release, 63(1-2), 19-30.
40- Pfister, C. U., Martoni, A., Zamagni, C., Lelli, G., De Braud, F., Souppart, C., ... & Hornberger, U. (2001). Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara®) in breast cancer patients. Biopharmaceutics & drug disposition, 22(5), 191-197.
41- Vincenzi, B., Armento, G., Spalato Ceruso, M., Catania, G., Leakos, M., Santini, D., ... & Tonini, G. (2016). Drug-induced hepatotoxicity in cancer patients-implication for treatment. Expert opinion on drug safety, 15(9), 1219-1238.
42- Mast, N., Lin, J. B., & Pikuleva, I. A. (2015). Marketed drugs can inhibit cytochrome P450 27A1, a potential new target for breast cancer adjuvant therapy. Molecular pharmacology, 88(3), 428-436.
43- Li, Y. F., Fu, S., Hu, W., Liu, J. H., Finkel, K. W., Gershenson, D. M., & Kavanagh, J. J. (2007). Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. International Journal of Gynecological Cancer, 17(4), 739-763.
Article Sidebar
Published
Sep 14, 2024
Article Details
How to Cite
Muhammad Nadeem, Zain Ul Abideen, Samina Akbar, Rukhsana Sattar, & Nadia Akbar. (2024). AN INSTANCE GROWING OF BLOOD-PLASMA PROTEIN AND LIVER FUNCTION, BY CHEMOTHERAPEUTIC DOSE OF ANTICANCER DRUG ABRAXANE AND FAMARA IN BREAST CANCER PATIENTS OF HUMAN FEMALE. Journal of Population Therapeutics and Clinical Pharmacology, 31(9), 3165-3181. https://doi.org/10.53555/vcxjm654
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Author Biographies
Muhammad Nadeem
Department of Zoology, Ghazi University, D G Khan
Zain Ul Abideen
Institute Of Zoology, Bahauddin Zakriyy University, Multan, Pakistan
Samina Akbar
Department of Zoology, Ghazi University, D G Khan
Rukhsana Sattar
Department of Zoology, Ghazi University, D G Khan
Nadia Akbar
Department of Zoology, Ghazi University, D G Khan
How to Cite
Muhammad Nadeem, Zain Ul Abideen, Samina Akbar, Rukhsana Sattar, & Nadia Akbar. (2024). AN INSTANCE GROWING OF BLOOD-PLASMA PROTEIN AND LIVER FUNCTION, BY CHEMOTHERAPEUTIC DOSE OF ANTICANCER DRUG ABRAXANE AND FAMARA IN BREAST CANCER PATIENTS OF HUMAN FEMALE. Journal of Population Therapeutics and Clinical Pharmacology, 31(9), 3165-3181. https://doi.org/10.53555/vcxjm654